LIVER CIRRHOSIS IS NOT ASSOCIATED WITH ATROPHY OF THE SMALL INTESTINAL VILLI

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。乳糜泻最可靠的标志是发现由谷蛋白的麦胶蛋白部分引起的小肠黏膜紊乱，并通过去除饮食中的麦胶蛋白来改善。在普通人群中，肌内膜抗体（EMA）和人组织转谷氨酰胺酶抗体（hTTG）对乳糜泻具有高度敏感性和特异性。肝病（LD）引起许多非特异性抗体，LD，特别是肝硬化，可能改变粘膜结构。在LD中，既没有对CD的血清学测试的有效性的验证，也没有小肠黏膜结构的范围的发现的报道。如果要用活检结果来诊断这些患者的乳糜泻，则需要证实小肠结构未因肝硬化而改变。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The most reliable marker for CD is the finding of disordered small intestinal mucosa induced by the gliadin fraction of gluten and improvement by removal of dietary gliadin. Endomysial Antibody (EMA) and human Tissue Transglutaminase antibody (hTTG) are highly sensitive and specific for CD in the general population. Liver disease (LD) elicits a number of non-specific antibodies, and LD, especially cirrhosis, may alter mucosal architecture. In LD, neither validation of the utility of serologic tests for CD nor the range of findings of small bowel mucosal architecture has been reported. Verification that small bowel architecture is unaltered by cirrhosis, is required if biopsy findings are to be used to establish a diagnosis of CD in these patients.